James E Fritz - McCordsville IN Philip A Hipskind - New Palestine IN Stephen W Kaldor - Indianapolis IN Karen L Lobb - Indianapolis IN James A Nixon - Indianapolis IN
This invention provides a series of substituted propanamines useful as tachykinin receptor antagonists. This invention also provides methods employing these substituted propanamines as well as pharmaceutical formulations comprising these compounds.
2-Acylaminopropanamines As Tachykinin Receptor Antagonists
James E Fritz - McCordsville IN Philip A Hipskind - New Palestine IN Stephen W Kaldor - Indianapolis IN Karen L Lobb - Indianapolis IN James A Nixon - Indianapolis IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 31405
US Classification:
514415, 514412, 548455, 548504, 548506
Abstract:
This invention provides compounds of the Formula I: which are useful as tachykinin receptor antagonists. This invention also provides methods employing these compounds, as well as pharmaceutical formulations comprising these compounds.
Sung Y. Cho - Indianapolis IN Thomas A. Crowell - Indianapolis IN Bruce D. Gitter - Carmel IN Philip A. Hipskind - New Palestine IN J. Jeffry Howbert - Bellevue WA Karen L. Lobb - Indianapolis IN Brian S. Muehl - Indianapolis IN James A. Nixon - Indianapolis IN
This invention provides a novel series of non-peptidyl compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.
Piperidinyl And Piperazinyl Tachykinin Receptor Antagonists
Sung Y. Cho - Indianapolis IN Thomas A. Crowell - Indianapolis IN Bruce D. Gitter - Carmel IN Philip A. Hipskind - New Palestine IN J. Jeffry Howbert - Bellevue WA Karen L. Lobb - Indianapolis IN Brian S. Muehl - Indianapolis IN James A. Nixon - Indianapolis IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 31454
US Classification:
51425409, 514316, 514326, 544373, 546187, 546201
Abstract:
This invention provides a novel series of non-peptidyl compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.
Sung Y. Cho - Indianapolis IN, US Thomas A. Crowell - Indianapolis IN, US Bruce D. Gitter - Carmel IN, US Philip A. Hipskind - New Palestine IN, US J. Jeffry Howbert - Bellevue WA, US Karen L. Lobb - Indianapolis IN, US Brian S. Muehl - Indianapolis IN, US James A. Nixon - Indianapolis IN, US
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K031/4045 C07D209/20
US Classification:
51425409, 514316, 514323, 544373, 546187, 546201
Abstract:
This invention provides a novel series of non-peptidyl compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.
Thiophene-Amd Thiazolesulfonamides As Antineoplastic Agents
Cora Sue Grossman - Indianapolis IN, US Philip Arthur Hipskind - New Palestine IN, US Ho-Shen Lin - Indianapolis IN, US Karen Lynn Lobb - Indianapolis IN, US Beatriz Lopez de Uralde Garmendia - Madrid, ES Jose Eduardo Lopez - Fishers IN, US Mary Margaret Mader - Fishers IN, US Michael Enrico Richett - Indianapolis IN, US Chuan Shih - Carmel IN, US Alfonso De Dios - Madrid, ES
Chuan Shih - Carmel IN, US Cora Sue Grossman - Indianapolis IN, US Karen Lynn Lobb - Indianapolis IN, US Thomas Hughes Corbett - Gross Pointe Park MI, US Ho-Shen Lin - Indianapolis IN, US Philip Arthur Hipskind - New Palestine IN, US
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 31/165 C07C 303/00
US Classification:
514617, 564 91
Abstract:
The present invention provides antitumor compounds of the formula (I), and antitumor methods.
Multicyclic Compounds For Use As Melanin Concentrating Hormone Antagonists In The Treatment Of Obesity And Diabetes
Jochen Ammenn - Hamburg, DE James Ronald Gillig - Indianapolis IN, US Lawrence Joseph Heinz - Pittsboro IN, US Philip Arthur Hipskind - New Palestine IN, US Michael Dean Kinnick - Indianapolis IN, US James Arthur Nixon - Indianapolis IN, US Carsten Ott - Bad Segeberg, DE Kenneth Allen Savin - Indianapolis IN, US Theo Schotten - Vierhoefen, DE Lawrence John Slieker - Carmel IN, US Nancy June Snyder - Lizton IN, US Michael Alan Robertson - Indianapolis IN, US
The present invention relates to a melanin concentrating hormone antagonist compound of formula I: (I); or a pharmaceutically acceptable salt, solvate, enantiomer or prodrug thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.
Lgenia
Ceo, Cso, Founder
Eli Lilly and Company Oct 1, 2012 - Dec 2017
Distinguished Research Fellow, Group Leader
Eli Lilly and Company Oct 2009 - Oct 2012
Senior Research Fellow, Group Leader
Eli Lilly and Company Oct 2005 - Oct 2009
Research Fellow, Group Leader
Eli Lilly and Company Oct 2004 - Oct 2005
Senior Research Advisor
Education:
Stanford University 1987 - 1991
Doctorates, Doctor of Philosophy, Chemistry
Butler University 1984 - 1986
Master of Science, Masters, Chemistry
Indiana University Bloomington 1978 - 1982
Bachelors, Bachelor of Science, Chemistry
Butler University
Masters
Skills:
Biotechnology Cell Chemistry Biomarker Discovery Clinical Development Clinical Research Clinical Trials Diabetes Drug Design Drug Development
Philip Hipskind, Senior Research Fellow at Eli Lilly and Company said, "Through the Initiative, we have forged strong links with IDRI's scientists with the aim of leveraging the unique drug discovery capabilities of each organization."